366 related articles for article (PubMed ID: 28294980)
1. MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.
Chou CK; Liu RT; Kang HY
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28294980
[TBL] [Abstract][Full Text] [Related]
2. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
[TBL] [Abstract][Full Text] [Related]
3. Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated Thyroid Carcinomas.
Matos ML; Pinto M; Alves M; Canberk S; Gonçalves A; Bugalho MJ; Papoila AL; Soares P
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540448
[TBL] [Abstract][Full Text] [Related]
4. BRAF mutation, selected miRNAs and genes expression in primary papillary thyroid carcinomas and local lymph node metastases.
Kalfert D; Ludvikova M; Pesta M; Hakala T; Dostalova L; Grundmannova H; Windrichova J; Houfkova K; Knizkova T; Ludvik J; Polivka J; Kholova I
Pathol Res Pract; 2024 Jun; 258():155319. PubMed ID: 38696857
[TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of Androgen Receptor-Suppressing miR-146b Expression in Papillary Thyroid Cancer Aggressiveness.
Chou CK; Chi SY; Hung YY; Yang YC; Fu HC; Wang JH; Chen CC; Kang HY
J Clin Endocrinol Metab; 2023 Oct; 108(11):2852-2861. PubMed ID: 37220080
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma.
Attia AS; Hussein S; Sameh H; Khalil A; Waley AB; Matar I; Sameh R
Cancer Biomark; 2024; 39(3):211-221. PubMed ID: 38073379
[TBL] [Abstract][Full Text] [Related]
7. The emerging role and clinical significance of circRNAs in papillary thyroid cancer.
Ma J; Xu J; Zhang X; Quan J
Front Endocrinol (Lausanne); 2024; 15():1351776. PubMed ID: 38544689
[TBL] [Abstract][Full Text] [Related]
8. Spatial transcriptomics reveals prognosis-associated cellular heterogeneity in the papillary thyroid carcinoma microenvironment.
Yan K; Liu QZ; Huang RR; Jiang YH; Bian ZH; Li SJ; Li L; Shen F; Tsuneyama K; Zhang QL; Lian ZX; Guan H; Xu B
Clin Transl Med; 2024 Mar; 14(3):e1594. PubMed ID: 38426403
[TBL] [Abstract][Full Text] [Related]
9. An enzyme-free sensing platform for miRNA detection and in situ imaging in clinical samples based on DNAzyme cleavage-triggered catalytic hairpin assembly.
Wang H; Shen M; Shen X; Liu J; Huang W; Jiang X; Liu H; Zeng S; Nan K; Cai S
Biosens Bioelectron; 2024 Jul; 256():116279. PubMed ID: 38608496
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of microRNA expression in thyroid tumors.
Yuan ZM; Yang ZL; Zheng Q
J Zhejiang Univ Sci B; 2014 Mar; 15(3):212-24. PubMed ID: 24599686
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-4728 mediated regulation of MAPK oncogenic signaling in papillary thyroid carcinoma.
Liu Z; Zhang J; Gao J; Li Y
Saudi J Biol Sci; 2018 Jul; 25(5):986-990. PubMed ID: 30108452
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology.
Fuziwara CS; Kimura ET
Int J Endocrinol; 2014; 2014():743450. PubMed ID: 25202329
[TBL] [Abstract][Full Text] [Related]
13. Engineering Multi-Walled Carbon Nanotube Therapeutic Bionanofluids to Selectively Target Papillary Thyroid Cancer Cells.
Dotan I; Roche PJ; Paliouras M; Mitmaker EJ; Trifiro MA
PLoS One; 2016; 11(2):e0149723. PubMed ID: 26901566
[TBL] [Abstract][Full Text] [Related]
14. SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility.
He H; Bronisz A; Liyanarachchi S; Nagy R; Li W; Huang Y; Akagi K; Saji M; Kula D; Wojcicka A; Sebastian N; Wen B; Puch Z; Kalemba M; Stachlewska E; Czetwertynska M; Dlugosinska J; Dymecka K; Ploski R; Krawczyk M; Morrison PJ; Ringel MD; Kloos RT; Jazdzewski K; Symer DE; Vieland VJ; Ostrowski M; Jarząb B; de la Chapelle A
J Clin Endocrinol Metab; 2013 May; 98(5):E973-80. PubMed ID: 23539728
[TBL] [Abstract][Full Text] [Related]
15. Identification of SUMOylation-related biomarkers in papillary thyroid carcinoma.
Li X; Ding Z; Tong Y
Cancer Cell Int; 2024 Apr; 24(1):149. PubMed ID: 38671425
[TBL] [Abstract][Full Text] [Related]
16. The Importance of miRNA in the Diagnosis and Prognosis of Papillary Thyroid Cancer.
Rogucki M; Buczyńska A; Krętowski AJ; Popławska-Kita A
J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682861
[TBL] [Abstract][Full Text] [Related]
17. Advances in targeted therapy and biomarker research in thyroid cancer.
Guo M; Sun Y; Wei Y; Xu J; Zhang C
Front Endocrinol (Lausanne); 2024; 15():1372553. PubMed ID: 38501105
[TBL] [Abstract][Full Text] [Related]
18. Long Non-Coding RNAs as Determinants of Thyroid Cancer Phenotypes: Investigating Differential Gene Expression Patterns and Novel Biomarker Discovery.
DeSouza NR; Jarboe T; Carnazza M; Quaranto D; Islam HK; Tiwari RK; Geliebter J
Biology (Basel); 2024 Apr; 13(5):. PubMed ID: 38785786
[TBL] [Abstract][Full Text] [Related]
19. Genomic alterations in thyroid cancer: biological and clinical insights.
Landa I; Cabanillas ME
Nat Rev Endocrinol; 2024 Feb; 20(2):93-110. PubMed ID: 38049644
[TBL] [Abstract][Full Text] [Related]
20. F10 Gene Expression and Ethnic Disparities Present in Papillary Thyroid Carcinoma.
Porter T; Kucheryavykh L
J Pers Med; 2024 May; 14(5):. PubMed ID: 38793106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
